159 related articles for article (PubMed ID: 15769665)
1. Epidermal growth factor receptor: is a novel therapeutic target for pancreatic cancer?
Dhar A; Mehta S; Banerjee S; Dhar K; Dhar G; Sengupta K; Ray G; Banerjee SK; Campbell DR
Front Biosci; 2005 May; 10():1763-7. PubMed ID: 15769665
[TBL] [Abstract][Full Text] [Related]
2. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
[TBL] [Abstract][Full Text] [Related]
3. Targeting EGFR in pancreatic cancer treatment.
Troiani T; Martinelli E; Capasso A; Morgillo F; Orditura M; De Vita F; Ciardiello F
Curr Drug Targets; 2012 Jun; 13(6):802-10. PubMed ID: 22458527
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor-targeted therapy for pancreatic cancer.
Xiong HQ; Abbruzzese JL
Semin Oncol; 2002 Oct; 29(5 Suppl 14):31-7. PubMed ID: 12422311
[TBL] [Abstract][Full Text] [Related]
5. Development of epidermal growth factor receptor targeted therapy in pancreatic cancer.
Qing L; Qing W
Minerva Chir; 2018 Oct; 73(5):488-496. PubMed ID: 29397631
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor-targeted therapy for pancreatic cancer.
Papageorgio C; Perry MC
Cancer Invest; 2007 Oct; 25(7):647-57. PubMed ID: 18027154
[TBL] [Abstract][Full Text] [Related]
7. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
[TBL] [Abstract][Full Text] [Related]
8. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy of the epidermal growth factor receptor in the treatment of pancreatic cancer.
Heeger S
Recent Results Cancer Res; 2008; 177():131-6. PubMed ID: 18084955
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Look at Anti-EGFR Agents in Pancreatic Cancer Therapy.
Verma HK; Kampalli PK; Lakkakula S; Chalikonda G; Bhaskar LVKS; Pattnaik S
Curr Drug Metab; 2019; 20(12):958-966. PubMed ID: 31755384
[TBL] [Abstract][Full Text] [Related]
11. Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.
Muslimov GF
Bull Exp Biol Med; 2008 Apr; 145(4):535-8. PubMed ID: 19110611
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor as a major anticancer drug target.
Caponigro F; Milano A; Ottaiano A; Iaffaioli RV
Expert Opin Ther Targets; 2006 Dec; 10(6):877-88. PubMed ID: 17105374
[TBL] [Abstract][Full Text] [Related]
13. New target therapies in advanced pancreatic cancer.
Cascinu S; Verdecchia L; Valeri N; Berardi R; Scartozzi M
Ann Oncol; 2006 May; 17 Suppl 5():v148-52. PubMed ID: 16807445
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
[TBL] [Abstract][Full Text] [Related]
15. Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice.
Scartozzi M; Pierantoni C; Berardi R; Squadroni M; Cascinu S
Expert Opin Ther Targets; 2006 Apr; 10(2):281-7. PubMed ID: 16548776
[TBL] [Abstract][Full Text] [Related]
16. Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways.
Tagliaferri P; Tassone P; Blotta S; Viscomi C; Grillone F; Budillon A; Caraglia M; Venuta S
Curr Drug Targets; 2005 May; 6(3):289-300. PubMed ID: 15857289
[TBL] [Abstract][Full Text] [Related]
17. HER family inhibitors in pancreatic cancer: current status and future directions.
Berz D; Miner T; McCormack E; Safran H
Expert Opin Ther Targets; 2007 Mar; 11(3):337-47. PubMed ID: 17298292
[TBL] [Abstract][Full Text] [Related]
18. Possible role of epidermal growth factor receptors in the therapy of pancreatic cancer.
Aggarwal S; Gupta S; Gupta MK; Murthy RS; Vyas SP
Crit Rev Ther Drug Carrier Syst; 2011; 28(4):293-356. PubMed ID: 21967400
[TBL] [Abstract][Full Text] [Related]
19. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway.
Yang L; Lin S; Kang Y; Xiang Y; Xu L; Li J; Dai X; Liang G; Huang X; Zhao C
J Exp Clin Cancer Res; 2019 Jan; 38(1):31. PubMed ID: 30674340
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.
Ciardiello F; Damiano V; Bianco R; Bianco C; Fontanini G; De Laurentiis M; De Placido S; Mendelsohn J; Bianco AR; Tortora G
J Natl Cancer Inst; 1996 Dec; 88(23):1770-6. PubMed ID: 8944008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
